The group has a special focus on the mechanisms and effects of natriuretic peptides and cGMP-mediated signalling - with the aim of providing the scientific basis for novel approaches to pharmacological treatment of cardiovascular diseases.
In this process, the group is also screening for and developing ligands targeting proteins in the signalling pathway with the ambition to treat cardiovascular diseases.
Projects
- CyTOheart: Cytohesins in the heart – regulation of natriuretic peptide signaling
- Novel therapy for treatment-resistant hypertension
- Mechanism of action of novel NPR-A activators for treatment of cardiovascular diseases
- Effects of natriuretic peptides and phosphodiesterases on contractility
- Natriuretic peptides and cardiac mitochondrial function
Externally funded projects
- Research Council of Norway BIOTEK2021 (verification funding)
- Young Research Talents (FRIPRO); Norwegian Council on Cardiovascular Diseases
International cooperation
Selected partners:
- Adrian Hobbs, Barts and London School of Medicine, Queen Mary University of London, England
- Lincoln R Potter, College of Biological Sciences, University of Minnesota, Minneapolis, USA
- Waldemar Kolanus, Life and Medical Sciences Institute (LIMES), Molecular Immunology and Cell Biology, University of Bonn, Germany